Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth

Catheter Precision, Inc. (NYSE American: VTAK) today announced transformational balance sheet improvements through new institutional capital commitments supporting the Company’s next phase of growth.
Nasdaq

Catheter Precision, Inc. Announces the Presentation of the First Clinical Data on LockeT

FORT MILL, SC / ACCESSWIRE / February 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US-based medical device company focused on novel electrophysiology products, announced ...
Yahoo Finance

Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the best stocks to buy and hold for the next 6 months. On February 10, Guggenheim raised its price target for Praxis Precision Medicines Inc.
Nasdaq

Catheter Precision, Inc. Announces Receipt of Audit Opinion with Going Concern Doubt

Catheter Precision announced its audit opinion raised concerns about ongoing financial stability, as detailed in its recent 10-K report. Catheter Precision, Inc. has announced that its 2024 annual ...
Seeking Alpha

Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025

This data was produced from a multi-center study that enrolled 125 patients. The data demonstrates that VIVO was over 94% accurate, assisted physicians in determining workflow when used pre-procedure, ...

Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best hot stocks to buy according to analysts. On February 19, Praxis Precision Medicines reported the financial results for Q4 2025, ending ...